Drug intelligence / Profile preview

nilvadipine

Development stage
Phase 3
Lead developer
Archer Pharmaceuticals
Modality
Small Molecules
Administration
Oral
01

Overview

Nilvadipine is a dihydropyridine calcium channel blocker used primarily to treat hypertension and other vascular disorders such as Prinzmetal's angina and Raynaud's phenomenon. It acts by selectively blocking L-type calcium channels in vascular smooth muscle cells, leading to vasodilation and reduced blood pressure. Compared to other dihydropyridines like nifedipine, nilvadipine has higher vascular selectivity, a longer duration of action, and less cardiodepressive effect. It has also been investigated for potential disease-modifying effects in Alzheimer's disease due to its ability to reduce amyloid production, increase cerebral blood flow, and exhibit anti-inflammatory and anti-tau activity in preclinical studies[1][3][5][7].

Brand names
NilvadNivadil
Other names
nilvadipinonilvadipinum
02

Targets

CACNA1D (Voltage-dependent L-type calcium channel subunit alpha-1D)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)

Beyond the preview

Go deeper on nilvadipine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on nilvadipine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call